The Goldman Sachs Group initiated coverage on shares of LumiraDx (NASDAQ:LMDX – Get Rating) in a research report report published on Monday, The Fly reports. The brokerage issued a neutral rating on the stock.
Separately, Raymond James cut their target price on shares of LumiraDx from $4.00 to $3.50 and set an outperform rating on the stock in a research note on Friday, November 11th.
Get LumiraDx alerts:LumiraDx Price Performance
Shares of LMDX opened at $0.94 on Monday. LumiraDx has a fifty-two week low of $0.77 and a fifty-two week high of $10.42. The firm's 50 day moving average price is $1.09 and its 200 day moving average price is $1.63. The company has a market cap of $42.46 million, a P/E ratio of -0.66 and a beta of 1.05. The company has a quick ratio of 1.63, a current ratio of 2.91 and a debt-to-equity ratio of 20.12.
Institutional Investors Weigh In On LumiraDx
A number of large investors have recently modified their holdings of the company. Balyasny Asset Management LLC increased its position in shares of LumiraDx by 36,072.9% in the 3rd quarter. Balyasny Asset Management LLC now owns 3,771,385 shares of the company's stock valued at $3,847,000 after purchasing an additional 3,760,959 shares during the last quarter. Pathstone Family Office LLC purchased a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $47,000. Bill & Melinda Gates Foundation purchased a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $14,600,000. Citadel Advisors LLC purchased a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $39,000. Finally, Seven Grand Managers LLC purchased a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $191,000.About LumiraDx
(Get Rating)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
Further Reading
- Get a free copy of the StockNews.com research report on LumiraDx (LMDX)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.